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Abstract 
Gold nanoparticles (AuNPs), which have been widely used for the delivery of photosensitizers 
for photodynamic therapy (PDT) of cancer, can be dispersed in aqueous solutions, improving the 
delivery of the hydrophobic photosensitizer into the body. Furthermore, the large surface of 
AuNPs can be functionalized with a variety of ligands, including proteins, nucleic acids and 
carbohydrates, that allow selective targeting to cancer tissue. In this study, gold nanoparticles 
were functionalized with a mixed monolayer of a zinc phthalocyanine and a lactose derivative. 
For the first time, a carbohydrate was used with a dual purpose, as the stabilizing agent of the 
gold nanoparticles in aqueous solutions and as the targeting agent for breast cancer cells. The 
functionalization of the phthalocyanine-AuNPs with lactose led to the production of water-
dispersible nanoparticles that are able to generate singlet oxygen and effect cell death upon 
irradiation. The targeting ability of lactose of the lactose-phthalocyanine functionalized AuNPs 
was studied in vitro towards the galectin-1 receptor on the surface of breast cancer cells. The 
targeting studies showed the exciting potential of lactose as a specific targeting agent for 
galactose-binding receptors overexpressed on breast cancer cells. 
 
Introduction 
Carbohydrates are present on the surface of human cells in the form of glycans; 
oligosaccharides either bound to proteins or lipids on the surface of the cells, or free within the 
tissue.[1,2] The surface of the cells also presents lectins, carbohydrate-binding proteins that 
recognize glycans in a specific manner via their carbohydrate-recognizing domain (CRD).[1–3] 
Glycans and lectins are involved in many important roles in an organism,[4] including embryonic 
development, cell growth, differentiation and adhesion, apoptosis, cell signaling, cell-cell 
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recognition, interactions between cells and the extracellular matrix and the regulation of host-
pathogen interactions, amongst others.[1–3,5] It is known that changes in the phenotypic 
distribution of glycans and lectins is linked with cancer.[3,5–7] The changes in the expression of 
glycans and lectins can be related to the under- or over-expression of the enzymes responsible 
for their biosynthesis, glycosyltransferases and glycosidases, as well as their localization within 
the Golgi apparatus, to the expression of oncofetal antigens only present in embryonic cells and 
cancer cells, but not in healthy adult tissue, or to changes in the carbohydrate structure.[2,3,6,8] 
Therefore, the aberrant glycosylation patterns in cancer cells can be used for targeted cancer 
therapy. Such targeting could be performed using carbohydrates to target endogenous lectins, 
i.e., direct lectin-targeting or glycotargeting, or using lectins to target glycoconjugates expressed 
on the surface of the cancer cells, i.e., reverse lectin-targeting.[9–11] Targeted cancer therapies 
have been reported using both direct[12–19] and reverse[20–26] lectin-targeting.  
Galectins are β-galactoside-binding lectins whose over- or under-expression has been linked 
with cancer.[27–30] Fifteen different mammalian galectins have been identified to date.[31–33] 
Among them, overexpression of galectin-1 has been linked with breast cancer.[31,32,34–38] 
Galectin-1 has been correlated with an increased tumor aggressiveness and poor prognosis, due 
to its ability to promote cell adhesion, leading to metastasis.[31,32,39] It has been shown that the 
suppression of galectin-1 can prevent both tumor growth and metastasis.[34,36] Therefore, 
galectin-1 would be an ideal candidate for targeted cancer treatment, such as photodynamic 
therapy (PDT).  
Here, we present the use of a carbohydrate, lactose, to stabilize AuNPs in aqueous solutions and 
to specifically target the galectin-1 receptor overexpressed on the surface of breast cancer cells. 
Following previous reports by our group,[20,40,41] gold nanoparticles were synthesized and 
functionalized with a mixed monolayer of lactose and a zinc phthalocyanine (Pc) 
photosensitizer. Two Pcs were explored, differing in the length of the carbon chain that 
connects the Pc to the gold core, consisting of either 3 or 11 carbon atoms.[42] The lactose 
disaccharide is made up of glucose and galactose residues.  Galectin-1 has been shown to 
recognize and bind to both sugar units.[27] Therefore, lactose is potentially an ideal candidate as 
a ligand for targeted PDT. 
A known lactose-containing thiol derivative,[43] Figure 1a, was chosen to evaluate the potential 
targeting towards the galectin-1 receptor on breast cancer cells. Importantly, the lactose ligand 
was shown to stabilize the zinc phthalocyanine-functionalized gold nanoparticles (AuNPs) in 
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aqueous solutions. The phthalocyanines used for this study were two octa-alkyl substituted zinc 
(II) phthalocyanines, differing in the length of the carbon chain connecting the macrocycle to the 
disulfide bond, either three carbon atoms (C3Pc) or eleven carbon atoms (C11Pc).[42] Schematic 
representations of the synthesized gold nanoparticles functionalized with a mixed monolayer of 
lactose and either C3Pc (lactose-C3Pc-AuNPs) or C11Pc (lactose-C11Pc-AuNPs) are shown in 
Figure 1b and Figure 1c, respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 1. (a) Structure of the thiolated lactose ligand.[43] Schematic representation of the (b) 
lactose-C3Pc-AuNPs and (c) lactose-C11Pc-AuNPs. 
 
Experimental 
Materials and methods  
All reagents were of analytical grade, used as received and purchased from Sigma-Aldrich (UK) 
unless otherwise stated. Tetrahydrofuran (THF) and sterilized deionized water were purchased 
from Fisher Scientific (UK). Sodium chloride (NaCl), phosphate buffered saline (PBS) tablets, 
foetal bovine serum (FBS), 75 cm2 Nunc Easy tissue culture flasks with porous caps, Nunc 6-well 
multidishes, Nunc Nunclon™ Δ Surface 96-well microplates, 18 mm diameter glass coverslips 
and InCell ELISA colorimetric detection kit were purchased from Thermo Fisher Scientific (UK). 
Trypsin 0.25 % with ethylenediaminetetraacetic acid (EDTA), Gibco™ Molecular Probes™ 
(b) 
(a) 
(c) 
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soybean trypsin inhibitor, McCOY’s 5A phenol red-free medium containing L-glutamine, 
Dulbecco’s Modified Eagle Medium (DMEM), sodium pyruvate and L-glutamine (200 mM) were 
purchased from Invitrogen (UK). Mammary epithelial basal medium (MEBM) was purchased 
from Lonza (UK). CellTiter-Blue® cell viability assay was purchased from Promega (UK). Millex GP 
syringe drive filter units (0.22 μm) were purchased from Millipore Corporation (USA). Vivaspin™ 
500 (100 kDa MWCO; PES membrane) centrifuge columns were purchased from Sartorius 
Stedim Biotech (UK). Thiol-dPEG®4-acid (sPEG) was purchased from Stratech (UK). Staurosporine 
free base (> 99 %) was purchased from LC Laboratories (USA). Holey carbon film 300 mesh 
copper grids were obtained from Agar Scientific (UK). Rabbit monoclonal anti-galectin-1 
antibody was purchased from Abcam (UK). A JDS Uniphase 633 nm Helium-Neon (HeNe) laser 
(10 mW) was purchased from Edmund Optics (USA). SK-BR-3 human breast adenocarcinoma 
cells were purchased from LGC Standards and kindly provided by Prof Dylan Edwards (Norwich 
Medical School, University of East Anglia, UK). MDA-MB-231 human breast adenocarcinoma and 
MCF-10A human mammary epithelial cells were purchased from ATCC in partnership with LGC 
Standards. 
UV-vis spectra were recorded using a Hitachi U-3010 spectrophotometer at room temperature 
using quartz cuvettes with a 1 cm path length. Fluorescence excitation and emission spectra 
were obtained using a Hitachi F-4500 fluorescence spectrometer in quartz cuvettes with a 1 cm 
path length. For the plate assays, absorbance and fluorescence measurements were performed 
using a CLARIOstar® (BMG Labtech) microplate reader at room temperature. Transmission 
electron microscopy (TEM) images were obtained using a JEOL JEM-2010 Electron Microscope 
operating at 200 kV. Centrifugation of nanoparticle samples was performed using a Beckman 
Coulter Allegra™ X-22R centrifuge. Centrifugation of biological samples was performed using an 
Eppendorf 5810R centrifuge. Confocal microscopy was performed using a Carl Zeiss LSM 510 
META confocal laser scanning microscope.  
Phosphate buffered saline (PBS) was prepared by dissolving 10 PBS tablets in water (1 L). The 
solution was sterilized by autoclaving at 110 °C for 10 min. The final PBS solution contained 
Na2HPO4 (8 mM), potassium phosphate monobasic (KH2PO4; 1 mM), NaCl (160 mM), potassium 
chloride (KCl; 3 mM) and a pH of 7.3. MES buffer was prepared in water containing 2-(N-
morpholino)ethanesulfonic acid (MES; 50 mM) and Tween-20 (0.05 %). The pH of the MES 
buffer was adjusted to 5.5 using aqueous solutions of NaOH (5 M) and HCl (0.6 M). Imaging 
medium based on Hank’s balanced salt solution (HBSS) for the biological experiments was 
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prepared in water containing NaCl (120 mM), KCl (5 mM), CaCl2∙2H2O (2 mM), magnesium 
chloride hexahydrate (MgCl2∙6H2O; 1 mM), NaH2PO4 (1 mM), NaHCO3 (1 mM), 4-(2-
hydroxyethyl)piperazine-4-ethanesulfonic acid (HEPES; 25 mM), D-glucose (11 mM) and bovine 
serum albumin (BSA; 1 mg/mL). The pH of the imaging medium was adjusted to 7.4 using an 
aqueous solution of NaOH (1 M). Prior to use, all buffer solutions and imaging media were 
sterilized by filtration through Millex GP syringe driven filter units (0.22 μm). 
Synthesis of lactose-Pc-AuNPs 
Two zinc phthalocyanines (Pc) composed of either a three carbon-atom chain (C3Pc) or an 
eleven carbon-atom chain (C11Pc) connecting the macrocycle to the sulfur were prepared as 
previously reported.[44,45] Gold nanoparticles (ca. 3-5 nm; AuNPs) were synthesized by sodium 
borohydride (NaBH4) reduction and functionalized with a mixed monolayer of a lactose 
derivative[43] together with either C11Pc or C3Pc. 
C11Pc (2.43 mg; 0.95 μmol) or C3Pc (2.22 mg; 0.95 μmol) were dissolved in dry THF (1.45 mL) 
and left to stir at room temperature. Then, lactose derivative (1 mL; 1.31 mM in water) was 
added to the C11Pc solution and stirred at room temperature for 5 min. HAuCl4∙3H2O (1.2 mg; 
3.0 μmol) was dissolved in dry THF (1.2 mL), added to the C11Pc-lactose mixture and stirred at 
room temperature for a further 5 min. Finally, a solution of NaBH4 (1.5 mg; 39.65 μmol) was 
prepared in water (1.2 mL) and added to the Pc-lactose solutions rapidly and under vigorous 
stirring. The reaction was stirred overnight (ca. 17 h) at room temperature in the dark at 
moderate speed. The resulting solution was a mixture of free Pc, AuNPs functionalized with Pc 
only, AuNPs functionalized with lactose only and AuNPs functionalized with both Pc and lactose. 
To purify the mixture, excess dry THF (6 mL) was added rapidly and under vigorous stirring, 
followed by centrifugation in Eppendorf tubes (1.5 mL) at 1,300 rpm for 2 min at 4 °C. The 
supernatant was collected and the brown pellet containing AuNPs functionalized only with 
lactose was discarded. The solvent mixture in the supernatant was evaporated by rotary 
evaporation under reduced pressure at 70 °C. For further purification, another aliquot of THF 
(5.4 mL) was added, followed by the same centrifugation and evaporation steps as explained 
previously. Once all the THF had been evaporated, MES buffer (3 mL) was added and the 
solubilization was assisted using an ultrasonic bath. The solution was centrifuged in Eppendorf 
tubes (1.5 mL) at 14,000 rpm for 30 min at 4 °C. The pellet containing free Pc and AuNPs 
functionalized only with Pc, and thus not soluble in an aqueous solution, was discarded. The 
supernatant containing the lactose-Pc-AuNPs was collected and filtered through a Millex GP 
  
6 
 
syringe driven filter unit (0.22 μm). The synthesized lactose-Pc-AuNPs were characterized using 
UV-vis spectroscopy, between 300-800 nm, and using TEM. A droplet of the functionalized 
AuNPs (20 μL) in MES buffer was placed onto a holey carbon film 300 mesh copper grid and left 
for 2 min to allow the nanoparticles to sediment onto the grid. Excess MES buffer was then 
removed by gently poking the side of the grid with filter paper. The grid was left to dry 
completely before imaging. 
Measurement of singlet oxygen production 
The lactose-Pc-AuNPs (511 μL) in MES buffer were placed in a 1.5 mL quartz cuvette together 
with ABMA (1 μL in methanol; 1 μM) and a magnetic stirrer bar. Oxygen was bubbled through 
the solution and the quartz cuvette was stoppered. The fluorescence emission spectrum of the 
initial solution was recorded, using an excitation wavelength of 380 nm, between 390-600 nm. 
The sample was then irradiated at 633 nm using a 10 mW HeNe laser for 40 min with 
continuous stirring. The laser was placed 50 cm away from the cuvette. The fluorescence 
emission spectrum of the sample was recorded every 5 min.  
Synthesis of control sPEG-Pc-AuNPs 
Gold nanoparticles were synthesised by NaBH4 reduction and functionalized with a mixed 
monolayer of either C11Pc or C3Pc and thiol-dPEG®4-acid (sPEG; 282.35 g/mol), a PEG ligand 
with a chain simulating the length of the lactose ligand. C11Pc (2.43 mg; 0.95 μmol) or C3Pc 
(2.22 mg; 0.95 μmol) were dissolved in dry THF (1 mL) and left to stir at room temperature. 
Then, sPEG (0.51 mg; 1.8 μmol) was dissolved in water (1.9 mL), added to each phthalocyanine 
solution and stirred at room temperature for 5 min. HAuCl4∙3H2O (1.2 mg; 3.0 μmol) was 
dissolved in water (1.2 mL), added to the Pc-sPEG mixtures and stirred at room temperature for 
a further 5 min. Finally, a solution of NaBH4 (1.5 mg; 39.65 μmol) was prepared in water (1.2 mL) 
and added to the gold salt plus Pc-sPEG solutions rapidly and under vigorous stirring. The 
reaction was stirred overnight (ca. 17 h) at room temperature in the dark at moderate speed. 
The resulting solution was purified following the method described above for the synthesis of 
lactose-Pc-AuNPs. 
In vitro cell work 
SK-BR-3 cells were routinely cultured in McCOY’s 5A phenol red-free medium containing L-
glutamine and supplemented with foetal bovine serum (FBS, 10 %); MDA-MB-231 cells were 
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routinely cultured in DMEM phenol red-free medium supplemented with L-glutamine (1 %), FBS 
(10 %) and sodium pyruvate (1 mM); and MCF-10A cells were routinely cultured in MEBM 
medium supplemented with cholera toxin (100 ng/mL). All cells were grown in an incubator at 
37 ˚C under a 5 % CO2 atmosphere. 
The cells were subcultured every 5 days, when they reached near confluence. The culture 
medium was discarded and the cells were washed with PBS (5 mL). The cells were dislodged 
from the flasks by addition of trypsin 0.25 % (1x) EDTA (5 mL) and incubation for either 5 min 
(SK-BR-3 and MDA-MB-231 cells) or 15 min (MCF-10A cells) at 37 °C under a 5 % CO2 
atmosphere. For SK-BR-3 and MDA-MB-231 cells, trypsin was deactivated by addition of the 
culture medium (5 mL) and removed by centrifugation at 800 relative centrifugal force (rcf) for 5 
min at 21 °C. For MCF-10A cells, trypsin was deactivated by addition of soybean trypsin inhibitor 
(5 mL; 1 mg/mL in PBS) and removed by centrifugation at 130 rcf for 7 min at 21 °C. The pellets 
containing the cells were then resuspended in either McCOY’s 5A medium, DMEM or MEBM, 
according to the cell line. 
In-Cell ELISA for the detection of galectin-1 on the surface of breast cancer cells 
An InCell enzyme linked immunosorbent assay (ELISA) to study the targeting ability of lactose 
towards the galectin-1 receptor on the surface of MDA-MB-231 and SK-BR-3 cells was 
performed.[46] MDA-MB-231 and SK-BR-3 cells were seeded onto a clear-bottom 96-well 
microplate at a concentration of 10×104 cells/mL (100 μL/well). The cells were incubated 
overnight at 37 °C under a 5 % CO2 atmosphere.  
The culture medium was removed and the cells were washed with PBS (100 μL) once. The 
nanoparticle samples, lactose-C11Pc-AuNPs and lactose-C3Pc-AuNPs (0.20 μM Pc) dissolved in 
FBS-free McCOY’s 5A medium containing L-glutamine, were then added (50 μL/well). 
Additionally, a solution of staurosporine (1 mM in dimethyl sulfoxide; DMSO) dispersed in FBS-
free McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was used as a positive control 
for cytotoxicity. Control cells not loaded with any AuNP samples were treated with FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL). The cells were incubated with the samples 
and controls for 3 h at 37 °C under a 5 % CO2 atmosphere. During the incubation period, the 
required buffers for the InCell ELISA were prepared following the instructions of the InCell ELISA 
kit.  
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Following incubation with the AuNPs, the samples were removed and the cells were washed 
with PBS (100 μL) three times and resuspended in McCOY’s 5A medium (100 μL) containing L-
glutamine and supplemented with FBS (10 %). The first part of the assay involved fixing the cells 
prior to addition of the primary antibody. From this point onwards, all incubation steps were 
performed with gentle shaking of the microplate and the plate contents were always removed 
using a micropipette to minimise cell loss. The culture medium was removed and formaldehyde 
(100 μL) was added to each well and incubated with the cells for 15 min at room temperature. 
The formaldehyde solution was removed and the plate was washed with 1X TBS (100 μL) twice. 
Permeabilization buffer (100 μL) was added to each well and incubated with the cells for 15 min 
at room temperature. The permeabilization buffer was removed and the cells were washed with 
1X TBS (100 μL) once. Quenching solution (100 μL) was added to each well and incubated with 
the cells for 20 min at room temperature. The quenching solution was then removed and the 
cells were washed with 1X TBS (100 μL) once.  
Following the fixing of the cells, blocking buffer (100 μL) was added and incubated with the cells 
for 30 min at room temperature. While the cells were incubated with blocking buffer, the 
primary anti-galectin-1 antibody was appropriately diluted to give a final concentration of 1 
μg/mL. Following incubation of the cells with blocking buffer, the blocking buffer was removed 
with a micropipette and anti-galectin-1 antibody (50 μL; 1 μg/mL) was added to each well. The 
microplate was sealed with a plate sealer and the cells were incubated with the primary 
antibody overnight (ca. 17 h) at 4 °C. 
The second part of the assay involved the development of an absorbance intensity signal for the 
levels of galectin-1 present in each sample. Following overnight incubation with the primary 
antibody, the blocking-washing solution was removed and the cells were washed with washing 
buffer (100 μL) three times. Horseradish peroxidase (HRP) conjugate (15 μL) was diluted with 
washing buffer (6 mL). The diluted HRP conjugate (100 μL) was added to each well and 
incubated with the cells for 30 min at room temperature. Following incubation, the HRP 
conjugate was removed and the plate was washed with washing buffer (200 μL) three times. 
The substrate 3,3’,5,5’-tetramethylbenzidine (100 μL; TMB) was added to each well and the 
plate was covered with aluminium foil. The plate was then incubated for 20 min at room 
temperature in the dark. TMB stop solution (100 μL) was then added to stop the reaction 
between the TMB Substrate and the HRP conjugate. The absorbance intensity was measured at 
450 nm. Background absorbance was corrected by subtracting the absorbance measurement 
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from the non-specific signal controls (i.e., well not incubated with primary antibody). All samples 
were analysed in triplicate.  
The third part of the assay involved the whole-cell staining of each well so the values of the 
galectin-1 receptor could be normalised to cell number. The plate contents were emptied and 
the plate was washed with water (200 μL) twice. Janus Green Whole-Cell Stain (100 μL) was 
added to each well and incubated for 5 min at room temperature. The stain was then removed 
and the plate was washed with water (200 μL) five times to remove all excess stain. Elution 
buffer (100 μL) was added to each well and incubated for 10 min at room temperature. The 
absorbance intensity was then measured at 615 nm. Background absorbance was corrected by 
subtracting the absorbance measurement from the culture medium alone. All samples were 
analysed in triplicate. To obtain the values of galectin-1 expression normalised to cell number in 
each well, the corrected absorbance values at 450 nm were divided by the corrected 
absorbance values at 615 nm. 
Cell viability assays: CellTiter-Blue® and MTT assays 
SK-BR-3, MDA-MB-231 and MCF-10A cells were seeded onto two white-bottom 96- well 
microplates at a concentration of 20×104 cells/mL (100 μL/well). The cells were incubated for ca. 
48 h at 37 °C under a 5 % CO2 atmosphere.  
The culture medium was removed using a micropipette and the cells were washed once with 
PBS (100 μL). The nanoparticle samples, lactose-C11Pc-AuNPs, lactose-C3Pc-AuNPs, C11Pc-
sPEG-AuNPs and C3Pc-sPEG-AuNPs, at various Pc concentrations in FBS-free McCOY’s 5A 
medium containing L-glutamine were then added (50 μL/well). Additionally, a solution of 
staurosporine (1 mM in DMSO) dispersed in FBS-free McCOY’s 5A medium containing L-
glutamine (50 μL; 20 μM) was also used as a positive control for cytotoxicity. Control cells 
without any nanoparticles loaded were treated with FBS-free McCOY’s 5A medium containing L-
glutamine. The cells were incubated with the samples and controls for 3 h at 37 °C under a 5 % 
CO2 atmosphere.  
Following incubation with the functionalised nanoparticles, the samples were removed and the 
cells were washed with PBS (100 μL) three times. The cells were then resuspended in complete 
McCOY’s 5A medium (100 μL) containing L-glutamine and supplemented with FBS (10 %). At this 
point, one of the plates was irradiated at 633 nm using a 10 mW HeNe laser fitted with a 
biconvex diverging lens for 6 min per well. The laser was located 50 cm above the 96-well plate, 
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giving an irradiance of 29 mW/cm2 and a total light dose of 10.5 J/cm2. The plate not being 
irradiated was kept covered in aluminium foil in the dark. The cells were further incubated for 
ca. 48 h at 37 °C under a 5 % CO2 atmosphere prior to measuring cell viability. 
CellTiter-Blue® cell viability assay: Following incubation post-PDT treatment, CellTiter-Blue® 
reagent (20 μL) was added to each well and incubated for 4 h at 37 °C under a 5 % CO2 
atmosphere. Fluorescence emission was then measured at 594 nm following excitation at 561 
nm using a CLARIOstar® (BMG Labtech) microplate reader at room temperature. Background 
fluorescence was corrected by subtracting fluorescence emission from McCOY’s 5A medium 
alone incubated with CellTiter-Blue®. Cell viability was calculated as a percentage of non-
treated, non-irradiated cells. All samples were analysed in triplicate. Statistical significance 
between means was determined using a two-tailed Student’s t-test and P values < 0.05 were 
considered significant.[47]  
MTT cell viability assay: Following incubation post-PDT treatment, MTT reagent (3-
(4,5,dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (10 μL; 5 mg/mL in PBS) was added 
to each well and incubated for 4 h at 37 °C under a 5 % CO2 atmosphere. The medium was then 
removed from the wells using a micropipette and the MTT formazan crystals were washed with 
PBS (100 μL) once and dissolved in culture-grade DMSO (200 μL). The contents of the wells were 
transferred to clear-bottom Nunc Nunclon™ Δ Surface 96- well microplates. The absorbance 
intensity was then measured at 560 nm. Background absorbance was corrected by subtracting 
the absorbance measurement from McCOY’s 5A medium alone incubated with MTT. Cell 
viability and statistical significance were calculated as explained above. 
Laser scanning confocal microscopy 
SK-BR-3 and MDA-MB-231 cells were seeded onto 18 mm diameter glass coverslips inside 6-well 
multidishes at a concentration of 2×104 cells/mL (3 mL/well). The cells were incubated for ca. 
48 h at 37 °C under a 5 % CO2 atmosphere. The culture medium was removed and the cells were 
washed once with PBS (1 mL). Lactose-C3Pc-AuNPs (0.17 μM C3Pc) dissolved in FBS-free 
McCOY’s 5A medium containing L-glutamine were added (1 mL/well). Control cells not loaded 
with nanoparticles were treated with FBS-free McCOY’s 5A medium containing L-glutamine (1 
mL). SK-BR-3 cells were incubated with the lactose-C3Pc-AuNPs and the control for 3 h at 37 °C 
under a 5 % CO2 atmosphere. MDA-MB-231 cells were incubated with the lactose-C3Pc-AuNPs 
and the control for either 3 h or 24 h at 37 °C under a 5 % CO2 atmosphere. 
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Following incubation with the samples, the cells were washed with PBS (1 mL) three times. They 
were then resuspended in complete McCOY’s 5A medium (2 mL) for SK-BR-3 cells or DMEM 
(2 mL) for MDA-MB-231 cells. The cells were further incubated for 19 h at 37 °C under a 5 % CO2 
atmosphere. For imaging with the confocal microscope, a Carl Zeiss LSM 510 META confocal 
laser scanning microscope was used. The 18 mm coverslips were placed in a Ludin chamber, 
which was securely tightened. The cells on the coverslips were washed with imaging medium 
(ca. 1 mL) three times and finally resuspended with imaging medium (ca. 1 mL). The Ludin 
chamber was fitted on a heating stage, at 37 °C, in the confocal microscope. A 633 nm HeNe 
laser was used to excite the Pc on the AuNPs and the fluorescence emission was collected in the 
red channel with a 650 nm long pass filter. Differential interference contrast (DIC) images were 
collected simultaneously using a 488 nm argon-ion laser. The images were acquired with a plan-
apochromat 63x/1.4 Oil DIC objective and processed using ImageJ/Fiji software.  
 
Results and discussion 
The synthesized lactose-C3Pc-AuNPs and lactose-C11Pc-AuNPs were characterized via TEM and 
UV-vis spectroscopy, as shown in Figure 2. Confirmation of the functionalization of the AuNPs 
with C3Pc or C11Pc was obtained by UV-vis spectroscopy (Figure 2e), which clearly shows the 
characteristic band of these phthalocyanines at ca. 698 nm.[20,40] Confirmation of the 
functionalization with lactose was obtained due to the facile dispersibility of the AuNPs in 
aqueous systems, which would otherwise be insoluble due to the hydrophobicity of the C3Pc 
and C11Pc. The aqueous stabilization of AuNPs with a carbohydrate, which is additionally used 
as a targeting agent for PDT, has not been reported previously. The lactose-C3Pc-AuNPs were 
found to be 3.10 ± 1.32 nm in size and the lactose-C11Pc-AuNPs were found to be 2.37 ± 1.65 
nm, as analyzed by TEM (Figure 2a-d). The nanoparticles were evaluated for production of 
singlet oxygen (1O2), using the 
1O2 probe 9,10-anthracenediyl-bis (methylene) dimalonic acid 
(ABMA). Both nanoparticle systems were shown to generate 1O2, as shown in Figure 2f, with the 
lactose-C3Pc-AuNPs producing more 1O2 than the lactose-C11Pc-AuNPs, which is thought to be 
due to surface enhanced effects with the C3Pc molecule.[42] 
Additionally, control AuNPs, used to evaluate the targeting ability of lactose within the lactose-
C3Pc-AuNPs, were synthesized. For the control AuNPs, the lactose ligand was substituted for a 
polyethylene glycol ligand of a short length (sPEG), thiol-dPEG®4-acid shown in Figure 3a, 
resembling the length of the lactose ligand. The purpose of the sPEG ligand was to facilitate the 
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solubility of the Pc-sPEG-AuNPs in aqueous solutions. Schematic representations of the 
synthesized gold nanoparticles functionalized with a mixed monolayer of sPEG and either C3Pc 
(C3Pc-sPEG-AuNPs) or C11Pc (C11Pc-sPEG-AuNPs) can be seen in Figure 3b and 3c, respectively, 
and the UV-vis characterisation of the C3Pc-sPEG-AuNPs and C11Pc-sPEG-AuNPs, in Figure 3d 
and 3e. 
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Figure 2. Characterization of the lactose-C3Pc-AuNPs and lactose-C11Pc-AuNPs. Transmission 
electron micrographs of a sample of (a) lactose-C3Pc-AuNPs and (c) lactose-C11Pc-AuNPs, where the 
scale bars represent (a) 20 nm and (c) 50 nm. Size distribution, showing the Gaussian fit, of the (b) 
lactose-C3Pc-AuNPs with an average size of 3.10 ± 1.32 nm (n = 466) and a median value of 2.72 ± 
1.74 nm; and (d) lactose-C11Pc-AuNPs with an average size of 2.37 ± 1.65 nm (n = 340) and a median 
value of 1.79 ± 2.71 nm. (e) UV-vis extinction spectra of the synthesized lactose-C3Pc-AuNPs (red 
line) and lactose-C11Pc-AuNPs (blue line). (f) Photobleaching of ABMA in the presence of lactose-
C3Pc-AuNPs (red line) and lactose-C11Pc-AuNPs (blue line) (0.734 μM) as a function of time; and no 
photobleaching observed for the control PEG-AuNPs (green line). Error bars represent the SD (n = 3) 
within a 95 % confidence interval. 
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Figure 3. (a) Structure of the thiol-dPEG®4-acid (sPEG). Schematic representation of the (b) C3Pc-
sPEG-AuNPs and (c) C11Pc-sPEG-AuNPs. UV-vis extinction spectrum of the synthesized (d) lactose-
C3Pc-AuNPs and (e) lactose-C11Pc-AuNPs. 
 
Two breast adenocarcinoma cell lines were explored, SK-BR-3 and MDA-MB-231 cells. The levels 
of galectin-1 on the surface of each cell line were estimated using an enzyme linked 
immunosorbent assay (ELISA). For this purpose, the cells were fixed and treated with anti-
galectin-1 antibody.[46] The ELISA showed higher levels of galectin-1 in MDA-MB-231 cells as 
compared to SK-BR-3 cells (Figure 4a). Therefore, the MDA-MB-231 cell line was expected to be 
the better target for the lactose-C3Pc-AuNPs or lactose-C11Pc-AuNPs than the SK-BR-3 cell line. 
The potential targeting ability of lactose-C3Pc-AuNPs and lactose-C11Pc-AuNPs towards the 
galectin-1 receptor was then investigated in each cell line using an ELISA. To evaluate the 
targeting by lactose, the cells were treated with either lactose-C3Pc-AuNPs or lactose-C11Pc-
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AuNPs for 3 hours and appropriately washed to remove all the non-internalized AuNPs prior to 
the ELISA. It was expected that the lactose would bind to the galectin-1 receptor and thus, the 
levels of galectin-1 on the lactose-Pc-AuNPs-treated cells would be lower than in control 
samples.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (a) InCell ELISA for the detection of galectin-1 on the surface of SK-BR-3 and MDA-MB-231 
cells. (b-c) InCell ELISA for the evaluation of the targeting ability of lactose towards galectin-1 on the 
surface of (b) MDA-MB-231 cells and (c) SK-BR-3 cells. The samples were incubated with either 
lactose-C11Pc-AuNPs (C11Pc) or lactose-C3Pc-AuNPs (C3Pc) for 3 h. Figures a-c show the normalised 
values of galectin-1 per cell in each sample. Error bars represent the SD (n = 3) within a 95 % 
confidence interval. Statistical significance is indicated by * at P < 0.004, obtained using a two-tailed 
Student’s t-test, where P < 0.05 is considered statistically significant. 
 
The results, as shown in Figure 4b-c, indicate targeting of the galectin-1 receptor only for the 
MDA-MB-231 cells when they were incubated with lactose-C3Pc-AuNPs, but not the lactose-
C11Pc-AuNPs. As expected from the results shown in Figure 4a, there is no apparent targeting of 
the SK-BR-3 cells for either of the nanoparticle conjugates. The fact that there is no recognition 
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effective targeting ligand. There are other galactose-binding receptors on the surface of the 
cells. It has been reported that the glucose transporter 1 also binds galactose,[18] and thus it 
could be a potential targeting receptor recognised by the lactose-Pc-AuNPs. Glucose transporter 
1 (GLUT1) has been reported to be overexpressed on breast cancer cells.[48–53] 
 
With consideration that only the lactose-C3Pc-AuNPs induced selective targeting of the galectin-
1 receptor, and that these nanoparticle conjugates produced more 1O2 than the lactose-C11Pc-
AuNPs (Figure 2), the lactose-C3Pc-AuNPs were studied in vitro using both MDA-MB-231 and SK-
BR-3 cells. The cells were incubated with either lactose-C3Pc-AuNPs or the control C3Pc-sPEG-
AuNPs for 24 hours, in order to maximise cell death, washed to remove all the non-internalized 
nanoparticles and irradiated with a 633 nm HeNe laser for 6 minutes. The cells were then 
subjected to CellTiter-Blue® cell viability assays to assess the PDT effect. Figure 5a shows the 
PDT effect in MDA-MB-231 cells. It can be seen that there is limited dark toxicity prior to 
irradiation with the laser. Additionally, post-PDT, the cell viability is reduced for samples treated 
with both lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs. However, though there is an indication 
that the lactose-C3Pc-AuNPs could induce more cytotoxicity, with a lower cell viability post PDT, 
the levels of cell death are similar for both the lactose-C3Pc-AuNPs and the C3Pc-sPEG-AuNPs. 
This suggests that the potential targeting between lactose and galectin-1 does not lead to a 
great increase in cytotoxicity post-PDT. For the SK-BR-3 cells, both lactose-C3Pc-AuNPs and 
C3Pc-sPEG-AuNPs induce similar levels of cell death following irradiation, leading to up to 95 % 
cell death (Figure 5b). However, a clear advantage of using the lactose-C3Pc-AuNPs is 
highlighted by the significantly reduced dark toxicity as compared to the C3Pc-sPEG-AuNPs. 
Non-cancerous mammary epithelial cells, MCF-10A cells, were also subjected to PDT via lactose-
C3Pc-AuNPs and C3Pc-sPEG-AuNPs. As it can be seen in Figure 5c, MCF-10A cells are not 
damaged by either lactose-C3Pc-AuNPs or C3Pc-sPEG-AuNPs before or after laser irradiation. 
The lack of cell death for non-cancerous MCF-10A cells is in contrast with the cell death 
obtained following PDT for cancerous MDA-MB-231 and SK-BR-3 cells. These results suggest 
that the presence of lactose in the lactose-C3Pc-AuNPs does not lead to an increased 
internalisation by non-cancerous cells, and therefore are good candidates for in vivo PDT of 
breast tumours. 
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Figure 5. CellTiter-Blue® cell viability assay for (a) MDA-MB-231 cells, (b) SK-BR-3 cells and (c) MCF-
10A cells incubated with C3Pc-sPEG-AuNPs (sPEG) or lactose-C3Pc-AuNPs (lactose) for 24 h. 
Untreated refers to cells only treated with growth medium. Cells were either irradiated with a 
633 nm HeNe laser (a) orange, b) light yellow, c) grey) or non-irradiated (a) dark cyan, b) green, c) 
purple). Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars represent 
the SD (n = 3) within a 95 % confidence interval. No statistically significant difference between C3Pc-
sPEG-AuNPs and lactose-C3Pc-AuNPs, as indicated by the P values (a) P < 0.09; b) P < 0.1) obtained 
using a two-tailed Student’s t-test, where P < 0.05 is considered statistically significant. 
 
Given that SK-BR-3 cells incubated with either lactose-C3Pc-AuNPs or C3Pc-sPEG-AuNPs at 0.2 
μM C3Pc for 24 h induce high levels of cytotoxicity, it is difficult to confirm that there is targeting 
via lactose. Therefore, a study of lower concentrations of C3Pc and different incubation periods 
(i.e., 3 h) would show whether there is any selective targeting due to the presence of the lactose 
on the nanoparticles. Figure 6 shows that lactose-C3Pc-AuNPs target the SK-BR-3 cells at lower 
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concentrations (0.05 μM C3Pc), as the cell death is statistically significantly different between 
lactose-C3Pc-AuNPs (97 %; Figure 6a) and C3Pc-sPEG-AuNPs (75 %; Figure 6b). 
 
 
 
 
 
 
 
Figure 6. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with (a) lactose-C3Pc-AuNPs 
or (b) C3Pc-sPEG-AuNPs (sPEG) for 3 h. Cells were either irradiated with a 633 nm HeNe laser (light 
yellow) or non-irradiated (green). Staurosporine (+ve St) was used as a positive control for 
cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence interval. Statistically 
significant difference between C3Pc-sPEG-AuNPs and lactose-C3Pc-AuNPs (0.05 μM C3Pc) is 
indicated by * at P < 0.003, obtained using a two-tailed Student’s t-test, where P < 0.05 is considered 
statistically significant. At higher concentrations, the difference is not statistically significant (P < 
0.2). 
 
Even though the targeting ability of lactose towards the galectin-1 receptor in MDA-MB-231 
cells only leads to a limited increase in cell death (Figure 5a), it can be clearly seen that the 
lactose-C3Pc-AuNPs are good candidates for PDT of breast cancer cells. The internalisation of 
the lactose-C3Pc-AuNPs is efficient by both MDA-MB-231 cells and SK-BR-3 cells, as shown by 
confocal microscopy (Figure 7). Additionally, it has been shown that the lactose-C3Pc-AuNPs 
induce effective cell death, especially when treating the SK-BR-3 cell line.  
(b) 
0
20
40
60
80
100
120
0           0.05        0.1         0.2       +ve St
 
 
C
e
ll
 V
ia
b
il
it
y
 /
 %
[C3Pc] in lactose-C3Pc-AuNPs / M
0
20
40
60
80
100
120
0           0.05        0.1         0.2       +ve St
 
 
C
e
ll
 V
ia
b
il
it
y
 /
 %
[C3Pc] in C3Pc-sPEG-AuNPs / M
(a) 
* 
* 
  
19 
 
 
Figure 7. Confocal fluorescence microscopy images of (a) MDA-MB-231 and (b) SK-BR-3 cells 
incubated with lactose-C3Pc-AuNPs for either (a) 24 h or (b) 3 h. The samples were imaged 24 h 
following incubation. Images taken from: 1) DIC, 2) fluorescence from C3Pc collected in the red 
channel (λex = 633 nm; above 650 nm), 3) composite images of DIC and fluorescence from C3Pc 
collected in the red channel. Scale bars represent 10 μm. 
 
Given the positive results seen with the lactose-C3Pc-AuNPs, it was decided to study the 
synthesized lactose-C11Pc-AuNPs (Figure 1c) in vitro to assess any potential targeting via lactose 
towards receptors other than galectin-1 on the surface of the MDA-MB-231 or SK-BR-3 cells. 
Initial cell viability studies with various concentrations of C11Pc within the AuNPs were 
performed, to evaluate the optimal concentration to be used for PDT. For this purpose, only SK-
BR-3 cells were incubated with the lactose-C11Pc-AuNPs for 24 h and irradiated with a 633 nm 
HeNe laser for 6 minutes. Figure 8 clearly shows that the optimal concentration for these type 
of nanoparticles is 0.25 μM, as it showed minimal dark toxicity while some cell kill could be seen 
post PDT. Higher concentrations of the C11Pc (0.5 and 0.7 μM) led to cytotoxicity prior to cell 
irradiation so these concentrations were not used for PDT treatment.  
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Figure 8. MTT cell viability assay for SK-BR-3 cells incubated with various concentrations of lactose-
C11Pc-AuNPs for 24 h. Cells were either irradiated with a 633 nm HeNe laser (light yellow) or non-
irradiated (green). Staurosporine (+ve St) was used as a positive control for cytotoxicity.  
 
Once the optimal concentration (0.25 μM, C11Pc) for PDT was determined, the cells were 
incubated with either lactose-C11Pc-AuNPs or C11Pc-sPEG-AuNPs for 24 hours, washed to 
remove all the non-internalized nanoparticles and irradiated with a 633 nm HeNe laser for 6 
minutes. The cells were then subjected to CellTiter-Blue® cell viability assays to assess the PDT 
effect. Figure 9a shows the effect in MDA-MB-231 cells. It can be seen that there is no cell death 
either before or after irradiation (i.e., post-PDT). For the SK-BR-3 cells, Figure 9b, both the 
lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs induce cell death following irradiation with 
negligible dark toxicity. Furthermore, the lactose-C11Pc-AuNPs induce more cytotoxicity (90 %) 
than the C11Pc-sPEG-AuNPs (61 %) post-PDT. This is an indication that the lactose-C11Pc-AuNPs 
are selectively targeting the SK-BR-3 cells, even though it appears not related to the galectin-1 
receptor (Figure 4). Other galactoside-binding receptors overexpressed on breast cancer cells, 
such as GLUT1, could be responsible for this selective targeting. 
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Figure 9. CellTiter-Blue® cell viability assay for (a) MDA-MB-231 cells and (b) SK-BR-3 cells incubated 
with C11Pc-sPEG-AuNPs (sPEG) or lactose-C11Pc-AuNPs (lactose) for 24 h. Untreated refers to cells 
only treated with growth medium. Cells were either irradiated with a 633 nm HeNe laser (a) orange, 
b) yellow) or non-irradiated (a) dark cyan, b) green). Staurosporine (+ve St) was used as a positive 
control for cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence interval. A 
statistically significant difference between C11Pc-sPEG-AuNPs and lactose-C11Pc-AuNPs is indicated 
by * at P < 0.006, obtained using a two-tailed Student’s t-test, where P < 0.05 is considered 
statistically significant. 
 
A study of concentrations of C11Pc with the lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs (< 0.2 
μM) did not achieve any cell death post PDT. These results are in contrast with the results seen 
for lower concentrations of the lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs (see Figure 6). 
Overall, the results reported here show that the lactose-C3Pc-AuNPs perform better than the 
lactose-C11Pc-AuNPs with both types of breast cancer cells studied.  
 
Conclusions 
In summary, we have shown that phthalocyanine functionalized gold nanoparticles can be 
stabilized and dispersed in aqueous solutions using a lactose derivative. These lactose-
phthalocyanine functionalized gold nanoparticles are biocompatible and good candidates for in 
vitro and, ultimately, in vivo PDT. The ability of the synthesized lactose functionalized gold 
nanoparticles to target the galectin-1 receptor overexpressed on some breast cancer cells was 
studied. For this purpose, two zinc phthalocyanine photosensitizers, C3Pc and C11Pc, were used 
to evaluate their PDT efficacy in vitro. It was shown that the galectin-1 receptor overexpressed 
on the surface of MDA-MB-231 cells can be targeted only via lactose-C3Pc-AuNPs, whereas 
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lactose-C11Pc-AuNPs do not appear to show any targeting ability. However, the use of either 
nanoparticles did not show any targeting via galectin-1 with SK-BR-3 cells. This result is 
consistent with the finding that SK-BR-3 cells do not overexpress galectin-1.  
In vitro PDT studies using the lactose-C3Pc-AuNPs were performed with both cell lines, MDA-
MB-231 and SK-BR-3 cells. Although targeting of the lactose-C3Pc-AuNPs towards galectin-1 was 
observed for the MDA-MB-231 cells, it did not correlate with an increase in cell death post PDT. 
Indeed, the cell death achieved was comparable to the control non-targeted C3Pc-sPEG-AuNPs. 
By contrast, SK-BR-3 cells were killed more efficiently by lactose-C3Pc-AuNPs (97 % cell death at 
0.05 μM C3Pc) than the control C3Pc-sPEG-AuNPs (75 % cell death at 0.05 μM C3Pc), indicating 
that lactose was selectively targeting the SK-BR-3 cells. Even though the targeting ability of the 
lactose-C3Pc-AuNPs in SK-BR-3 appears to be unrelated to the galectin-1 receptor, the presence 
of other targeting receptors on the cell surface should be studied to understand how this 
selective interaction is enhancing photodynamic therapy of breast cancer cells. In vitro PDT 
studies using the lactose-C11Pc-AuNPs showed comparable results to those observed with the 
lactose-C3Pc-AuNPs. The synthesized lactose-C11Pc-AuNPs were shown to induce no targeting 
towards the galectin-1 receptor on the MDA-MB-231 cells, thus leading to no internalization and 
no cell death post-PDT. However, the use of the lactose-C11Pc-AuNPs indicated targeting 
towards the SK-BR-3 cells, leading to significant levels of cytotoxicity (90 % at 0.2 μM C11Pc) as 
compared to the control C11Pc-sPEG-AuNPs (61 % at 0.2 μM C11Pc). These results suggest that 
the C3Pc photosensitizer should be used in preference to the C11Pc photosensitizer, given that 
it induces higher levels of cytotoxicity for both cell lines, at a lower photosensitizer 
concentration.  
This study shows that lactose can be successfully used to target breast cancer cells. The use of a 
carbohydrate as a targeting agent has several advantages over other biomolecules such as 
antibodies. Cancer cells can become resistant to antibodies due to genetic mutations, leading to 
innate or acquired resistance towards the treatment, as seen for the use of Herceptin to treat 
HER2 positive breast cancers.[54,55] Additionally, the present study has shown enhanced cell kill 
compared to previous work where other carbohydrates have been used for selective cancer 
targeting.[13,15] More importantly, we have successfully increased levels of cell death with lower 
irradiation periods and radiation doses (29 mW/cm2; 10.5 J/cm2 for 6 minutes) to those 
reported previously (50 mW/cm2; 90 J/cm2 for 30 minutes).[13] 
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In conclusion, the results reported show that the use of lactose to stabilize the hydrophobic 
phthalocyanine photosensitizer on the gold nanoparticles in aqueous solutions has clear 
advantages for targeted photodynamic therapy and suggests that other carbohydrates should 
be investigated for optimal targeting of ligands on cancer cells. 
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